New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.

6 Gastroenterology & Hepatology Volume 6, Issue 1, Supplement 1 January 2010 Multiple daily dosing of 5-ASA for UC has been a standard practice since the 1940s. However, these regimens can lead to poor patient adherence. Recently, several 5-ASA formulations have demonstrated non-inferiority to multiple daily dosing, including ethylcellulose-coated microgranules (Pentasa),1 Multi-Matrix delayed release tablets (Lialda),2 and delayedand extended-release granules (Apriso).3 In the ASCEND I, II, and III trials, a delayed-release 5-ASA formulation (Asacol) was investigated at doses of 2.4 and 4.8 g/day, to optimize therapy in specific patient populations.4-6 This same formulation is currently being evaluated for possible once-daily dosing in the maintenance setting. Two presentations at ACG provided new data on the efficacy of delayed-release 5-ASA. 1185 Once Daily Dosing of Delayed-Release Oral Mesalamine (400 mg Tablet) is as Effective as Twice Daily Dosing for Maintenance of Remission of Ulcerative Colitis: Results of the QDIEM Study W Sandborn, S Kane, J Korzenik, B Lashner, J Leighton, U Mahadevan, J Marion, M Safdi,